General Information of Drug (ID: DMZEECF)

Drug Name
Bradanicline
Synonyms
Bradanicline; 639489-84-2; TC-5619; Bradanicline (TC-5619); TC 5619; ATA-101; CHEMBL1258006; N-[(2S,3R)-2-(pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]octan-3-yl]-1-benzofuran-2-carboxamide; UM3821998K; 2-Benzofurancarboxamide, N-((2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo(2.2.2)oct-3-yl)-; 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-; Bradanicline [USAN:INN]; UNII-UM3821998K; Bradanicline (USAN/INN); BRADANICLINE [INN]; BRADANICLINE [USAN]; BRADANICLINE [WHO-DD]; SCHEMBL372929; ATA101; GTPL3969; DTXSID40213778; OXKRFEWMSWPKKV-GHTZIAJQSA-N; EX-A7201; BDBM50393247; TC5619; compound 7a [PMID 23126648]; DB06090; HY-18060; MS-25725; CS-0007204; TC-5619-238; D10613; (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide; (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]octan-3-yl)benzofuran-2-carboxamide; N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2-carboxamide
Indication
Disease Entry ICD 11 Status REF
Chronic cough MD12 Phase 2 [1]
Drug Type
Small molecule
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C22H23N3O2
Canonical SMILES
C1CN2CCC1C(C2CC3=CN=CC=C3)NC(=O)C4=CC5=CC=CC=C5O4
InChI
InChI=1S/C22H23N3O2/c26-22(20-13-17-5-1-2-6-19(17)27-20)24-21-16-7-10-25(11-8-16)18(21)12-15-4-3-9-23-14-15/h1-6,9,13-14,16,18,21H,7-8,10-12H2,(H,24,26)/t18-,21+/m0/s1
InChIKey
OXKRFEWMSWPKKV-GHTZIAJQSA-N
Cross-matching ID
PubChem CID
25147644
UNII
UM3821998K
DrugBank ID
DB06090
TTD ID
D9PC0O

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Agonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03622216) A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough. U.S.National Institutes of Health.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight